# Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC

Source: https://onco.cc/trials/nct04605913/  
OnCo record `nct04605913` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial in pancreatic cancer, run by Mayo Clinic, now recruiting.

## Summary

Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC is a phase 1/2, interventional study registered as NCT04605913 by Mayo Clinic, with a registry enrolment figure of 40 participants, started 2022-04-01 and due to reach its primary completion in 2027-10-01. Interventions recorded: Modified GCN+TTF treatment. Conditions listed: Pancreas Cancer; Metastatic Pancreatic Cancer; Pancreatic Adenocarcinoma; Metastatic Adenocarcinoma. Primary outcome: Safety of (m)-GCN+TTF. Pancreatic eligibility wording from the registry: "Histologically or cytologically confirmed pancreatic adenocarcinoma or adeno-squamous carcinoma with liver metastasis". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT04605913
- Phase: 1/2
- Setting: A Phase I/Ib Pilot Trial, Single Arm, Open Label, of Protein-Bound Paclitaxel, Cisplatin, and Gemcitabine (GCN) Combined With Tumor Treatment Fields (TTF) in Patient With Metastatic Pancreatic Adenocarcinoma
- Sponsor: Mayo Clinic
- Enrolled: 40

## Sources

- ClinicalTrials.gov NCT04605913: https://clinicaltrials.gov/study/NCT04605913

## Connected records

- cancers: [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct04605913.json